Lipopolysaccharide (LPS)-induced activation of Toll-like receptor 4 (TLR4) elicits the innate immune response and can trigger septic shock if excessive. Two antibodies (HT4 and HT52) inhibit LPS-induced human TLR4 activation via novel LPS binding-independent mechanisms. The HT52 epitope resides on leucine-rich repeat 2 (LRR2) and is a feature of many inhibitory antibodies; antigen specificity of HT4 does not reside in LRR2. Here, we identified an HT4 epitope on LRR13 located close to the TLR4 dimerization interface that plays a role in NFjB activation. HT4 and HT52 mutually enhanced TLR4 inhibition. LRR13 is a novel inhibitory epitope and may be useful for developing anti-TLR4 antibodies. Combination therapy with LRR2 and LRR13 may effectively inhibit TLR4 activation.
Innate immunity is the first line of defense against pathogenic microbes. The immune response commences with the recognition of conserved pathogenassociated molecular patterns by pathogen recognition receptors (PRRs) and progresses to the mounting of inflammatory responses to reduce the infectious burden and limit early pathogen dissemination [1] . PRR activation also upregulates antigen presentation, resulting in pathogen elimination and/or neutralization by antigen-specific lymphocytes [2] .
Toll-like receptors (TLRs) are well-characterized PRRs that play essential roles in the innate defense against many pathogenic microbes, including bacteria, fungi, and viruses [3] . TLR4 expressed on the cell surface recognizes lipopolysaccharide (LPS), a major cell wall component of gram-negative bacteria [4, 5] . TLR4 elicits host immune responses required for defense against bacterial infection; however, an excessive inflammatory response may trigger a systemic syndrome termed sepsis, which may cause multiple organ failure or death [6, 7] . Therefore, regulation of TLR4 signaling is required to mitigate the deleterious outcomes of an overwhelming inflammatory response. TLR4 targeting has attracted increasing attention in Abbreviations bio-, biotinylated; CDR, complementarity-determining region; FccR, Fc-c receptor; IP, immunoprecipitation; LPS, lipopolysaccharide; LRR, leucine-rich repeat; MD-2, myeloid differentiation 2; PRR, pathogen recognition receptor; sTLR4F, C-terminal FLAG-tagged secreted form of TLR4; stv, streptavidin; TLR4F, TLR4 tagged with a FLAG peptide at the C terminus; TLR4G, TLR4 tagged with a GFP at the C terminus; TLR, Toll-like receptor; WB, western blotting.
the context of anti-inflammatory medications for patients with infectious diseases [8] [9] [10] [11] [12] [13] .
Toll-like receptor 4 is a type I transmembrane receptor comprising 22 extracellular leucine-rich repeat (LRR) motifs and a cytoplasmic Toll/interleukin-1 receptor signaling domain [14] . A TLR4/myeloid differentiation 2 (MD-2) protein complex is required for LPS recognition and initiation of signaling [15, 16] . MD-2 interacts directly with LPS via a hydrophobic pocket, and controls the extent of TLR4 stimulation by LPS. This depends on the structure of lipid A, an essential LPS component [14] . LPS with six acyl chains and two phosphate groups triggers dimerization of the TLR4/ MD-2 complex, which then activates NFjB [14, 17] . LPS-mediated stimulation is greatly attenuated when the numbers of acyl chains and phosphate groups in lipid A are reduced [10] [11] [12] . Although stimulation-defective LPS analogs have been developed as competitive antagonists of TLR4/MD-2 [10] [11] [12] , no such drug has yet been successful in clinical trials of septic patients.
We previously produced over 20 mAbs against human TLR4 by immunizing TLR4-deficient mice [8, 13, 15] . We identified three mAbs (HT4, HT52, and HTB2) that potently inhibited LPS-activated TLR4/ MD-2-expressing cells [8, 13] . The mAbs do not competitively inhibit the binding of LPS to TLR4/MD-2, but rather prevents LPS-induced TLR4 internalization via an undetermined mechanism [8, 13] . Detailed molecular analysis of a panel of anti-TLR4 mAbs (including inhibitory and nonfunctional mAbs) showed that the epitope recognized by HT52 was characteristic of most inhibitory anti-TLR4 mAbs [13] . Thus, mAbs with epitope specificities similar to that of HT52 were consistently inhibitory (e.g., HTA125, the first inhibitory TLR4 mAb developed [18] ; and HTB2 that cross-blocks HT52 [13] ). The epitope inherent to inhibitory TLR4 mAbs was located on LRR2 of the TLR4 extracellular domain [13] . It became clear that HT4 was the only inhibitory mAb that did not recognize the LRR2 epitope.
As is true of other inhibitory mAbs, the HT4 epitope resides in the extracellular domain of TLR4, not on MD-2 [8] . Cross-blocking and biochemical analyses using TLR4 deletion mutants revealed that the HT4 epitope was distinct from that of HT52-type inhibitory mAbs, including HTA125 and HTB2; HT4 binding to TLR4 was not cross-blocked by any other inhibitory mAb or nonfunctional Ab [8] . This suggests that the TLR4 extracellular domain contains an additional site via which LPS-induced activation may be regulated. Therefore, identification of the HT4 epitope would reveal a structural target other than LRR2 for the design of anti-TLR4 mAb medications, and would improve the strategic approach toward regulation of TLR4 function. In the present study, we identified the primary sequence of the LRR containing the HT4-inhibitory epitope, and explored the role played by the LRR in TLR4 activation. In addition, we determined whether combinations of HT4 and HT52 enhanced the inhibition of LPS-activated TLR4/MD-2.
Materials and methods

Cells
CHO-DG44, HEK293, and Ba/F3 reporter cells expressing FLAG-tagged human TLR4/MD-2/CD14 and the NFjBresponsive luciferase reporter gene were kind gifts from K. Miyake (University of Tokyo, Tokyo, Japan) and were cultured as described previously [8, 13, 15] . Two types of TLR4 tagged with a GFP (TLR4G) or FLAG (TLR4F) peptide at the C terminus were produced by the electroporation of human TLR4G/pEF-BOS [8] and pBABEpuro vectors into the Ba/F3 reporter cells described above, followed by selection with puromycin.
Reagents and Abs
Lipopolysaccharide (Escherichia coli O:111) was purchased from Wako Pure Chemical Industries (Osaka, Japan). Mouse anti-human TLR4 mAbs (HT4 and HT52) and their biotinylated (bio-) derivatives were generated as described previously [8] . 
Construction of full-length and C-terminal FLAGtagged plasmids encoding secreted forms of TLR4 (sTLR4F)
A pEF-BOS vector expressing sTLR4F was constructed previously [13] . Chimeric sTLR4 vectors were constructed as described previously [13] . In brief, the N-terminal mouse and C-terminal human sTLR4 regions were amplified using the primers shown in Table S1 , separated on, and excised from, an agarose gel. The mouse and human fragments were annealed and extended employing PfuUltra TM HF DNA polymerase (Agilent Technologies). The first forward primer for murine TLR4 and the reverse primer for human TLR4 were then added and thermal cycling was repeated. The resultant PCR products were subcloned into the human sTLR4F/pEF-BOS vector [13] between the XhoI and HpaI sites (sTLR4F-LRR12), the HpaI and EcoRV sites (sTLR4F-LRR13, 14), or the HpaI and BamHI sites (sTLR4F-LRR18), respectively. Site-directed mutagenesis of the human sTLR4F/pEF-BOS vectors was performed using the primer sets (Mut 2, 3) listed in Table S2 . Mutated oligonucleotides of human TLR4 (Table S3) were synthesized and placed between the HpaI and EcoRV restriction sites (Mut 1, 4) or the EcoRI and HpaI sites (Mut 6) by Eurofins Genomics (Tokyo, Japan) and FASMAC (Atsugi, Japan), respectively, and subcloned into the human sTLR4F/pEF-BOS construct [13] .
Site-directed mutations in full-length human TLR4 were introduced by placing mutated oligonucleotides between the HpaI and EcoRV sites (Mut 8, 9; Genewiz, South Plainfield, NJ, USA; Table S3 ) followed by transfer to a pEF-BOS-based plasmid-expressing full-length wild-type TLR4 [19] .
Immunoprecipitation (IP) and western blotting (WB) of sTLR4F
The IP-WB was performed as described previously [13] . In brief, CHO-DG44 cells (2 9 10 5 ) were seeded onto a sixwell plate and cultured overnight. After changing the medium to Opti-MEM TM , the cells were transfected with the sTLR4F expression vector using Lipofectamine Ò 2000. Six hours later, the medium was replaced with CD CHO medium (Invitrogen) and the cells were cultivated for a further 2 days. The cultured medium was subjected to immunoprecipitation (IP) with agarose-immobilized FLAG-M2 (15 lL) or TLR4 mAbs (15 lg) conjugated with Protein G Sepharose Ò 4 Fast Flow (15 lL; GE Healthcare, Piscataway, NJ, USA). Following 1 h of incubation with gentle rotation, the protein-bound beads were washed three times with 20 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, and 0.1% (w/v) Triton X-100, and the bound proteins were eluted by boiling in Laemmli buffer. The proteins were resolved on a 7.5% (w/v) SDS/PAGE gel, transferred to an Immobilon Ò -P membrane (Millipore Co., Bedford, MA, USA), and probed with Bio-FLAG M2 mAb and HRPconjugated stv. Immunoreactive protein bands were visualized on X-ray film using a Chemi-Lumi One Super chemiluminescence kit (Nacalai Tesque, Kyoto, Japan).
TLR4 dimerization assay
Toll-like receptor 4 dimerization was detected using TLR4F/TLR4G/MD-2F/CD14-expressing Ba/F3-transfected cells as described previously [17] . In brief, cells were stimulated with LPS for 20 min, washed with PBS twice, and lysed in 20 mM Tris buffer (pH 7.5), 150 mM NaCl, 1 mM PMSF, 1% (w/v) Brij35, 0.5% (w/v) n-octyl-b-D-glucoside, and 0.5% (w/v) Triton X-100. A rabbit anti-GFP Ab-immobilized Affi-Gel 10 [17] was incubated with cell lysate, and coprecipitated TLR4F and TLR4G were detected by western blotting (WB) using a FLAG M2 mAb and rabbit anti-GFP Ab [17] , followed by an HRP-conjugated goat anti-(mouse IgG) Ab and anti-(rabbit IgG) Ab, respectively.
Results
Identification of the inhibitory epitope recognized by the anti-human TLR4 mAb HT4
Previous cross-blocking analysis indicated that the HT4 epitope did not overlap with that of the HT52-type inhibitory anti-TLR4 mAbs [8] . However, IP and flow cytometric analysis of cells expressing human TLR4 deletion mutants failed to identify the HT4 epitope domain because the HT4 mAb lost reactivity upon deletion of any N-terminal, central, or C-terminal domain of TLR4 [8] . The HT4 epitope thus seemed to be sensitive to intramolecular deletion. Additionally, deletion of some extracellular domains of TLR4 inhibits cell surface expression of the molecule [8, 13] . Post-translational modification is defective in intracellularly accumulated TLR4; the protein is improperly processed in the endoplasmic reticulum and Golgi. If a post-translational modification is indispensable for the expression of the HT4 epitope, the use of a deletion approach would be illogical.
We recently successfully identified the epitope recognized by the inhibitory mAb HT52 with the aid of a series of mouse-human chimeric forms of sTLR4F that lacked the transmembrane and cytoplasmic domains [13] . In general, any effect of conformation may be assumed to be less severe in chimerae of mammalian orthologs compared with intramolecular deletion mutants. As HT4 does not react with mouse TLR4 (as is also true of HT52) [8] , we took a chimeric approach and caused CHO cells to secrete a series of mouse-human chimeric sTLR4Fs (Fig. 1A) . The reactivities of chimeric sTLR4Fs were determined via IP using HT4, and WB using FLAG mAb, as described previously [13] . The sTLR4F-LRR12 chimera reacted with HT4, but reactivity was lost when LRR18 was replaced by the murine sequence (Fig. 1B) , suggesting that neither the N-terminal nor central domain (LRR1 to LRR12) is directly involved in epitope formation and that the N-terminal half of the C-terminal domain (from LRR13 to LRR18) contains the critical region. We further narrowed down the epitope by extending the murine region from LRR12 toward the C terminus. When replacement extended to the LRR13 region, HT4 lost reactivity to sTLR4F-LRR13 (Fig. 1B) . Thus, sTLR4F-LRR14 did not react with HT4. This suggested that the HT4 epitope lay within LRR13.
We next used site-directed mutagenesis to change several amino acids of the human LRR13 to those of the mouse, based on alignment of these sequences ( Fig. 2A) . HT4 reactivity was completely abolished in Mut 1 [i.e., upon replacement of KLKS (human amino acids 349-352) by DLPF (mouse amino acids (Fig. 2B) , but not in the other mutations (Mut 2 and 3) .
Aside from the HT4 epitope, LRR13 contains a sequence recognized by 15C1, an anti-human TLR4 mAb generated by another group [20] . The 15C1 epitope spans both LRR12 and LRR13 [20] . The critical amino acids of the HT4 epitope within LRR13 almost overlap with those of 15C1 (Fig. 2C, Table 1 ). To explore whether the antigen specificity of HT4 was identical to that of 15C1, we examined the HT4 reactivity of sTLR4F Mut 6 in which critical amino acids (Tyr 328 and Asn
329
) of 15C1 in LRR12 [20] were replaced with the murine residues (Lys 326 and His 327 ) (Fig. 2D) . Such mutation did not eliminate reactivity. Therefore, HT4 and 15C1 have distinct specificities, although the critical primary sequences in LRR13 overlap partially. Antigenic epitopes in the LRR and complementarity-determining region (CDR) sequences of HT4, HT52, and 15C1 are shown in Table 1 .
Functional role of LRR13 in TLR4 activation
LRR13 contains epitopes recognized by both the HT4 and 15C1 inhibitory anti-TLR4 mAbs. Notably, LRR13 is relatively rich in positively charged residues, such as lysine and arginine, some of which lie in the [14] . We thus explored the functional contribution of LRR13 to TLR4 activation. The basic amino acid and asparagine residues were changed to alanine (Fig. 3A) and the mutated full-length TLR4 expression plasmids (Mut 8 and Mut 9) were transfected into HEK293 cells together with the MD-2 expression plasmid. TLR4 activity was assessed using a dual-luciferase NFjB reporter assay (Fig. 3B) . Overexpression of wild-type TLR4 induced NFjB activation; such activation was less upon transfection of the Mut 9 plasmid in which all residues mentioned above were changed to alanine. However, the substitutions in Mut 8 did not abrogate activation, suggesting that LRR13 plays a functional role in TLR4 activation.
Impact of HT4 on LPS-induced TLR4 dimerization
LRR13 is located close to the interface created by the LPS-induced dimerization of two TLR4/MD-2 complexes. Therefore, we investigated the impact of HT4 on LPS-induced TLR4 dimerization as a potential inhibitory mechanism of the HT4 mAb. Ba/F3 cells transfected with TLR4F, TLR4G, MD-2, and CD14 were stimulated with LPS in the presence or absence of HT4, and a co-IP assay was performed using an anti-GFP Ab-immobilized gel and an anti-FLAG mAb [17] . Consistent with a previous report [17] , TLR4F coprecipitated with TLR4G in a dose-dependent manner when transfected cells were stimulated with LPS (Fig. 4) . However, this precipitation was not decreased but rather increased by treatment with HT4 in an LPS-independent manner. This result suggests that inhibition of LPS-induced TLR4 dimerization may not be the mechanism underlying inhibition of receptor activation by HT4.
Anti-human TLR4 mAbs exhibiting distinct epitope specificities mutually enhance TLR4 inhibition
As expected from our previous cross-blocking analysis [8] , we found that HT4 bound to an LRR (LRR13) distinct from that to which HT52 binds (LRR2). The fact that the inhibitory epitopes did not overlap allowed us to explore whether combinations of these mAbs would mutually enhance TLR4 inhibition. Ba/ F3-transfected cells expressing TLR4/MD-2/CD14 and NFjB-responsive luciferase were stimulated with LPS in the presence of HT4 or HT52 alone, or both (Fig. 5A) . Consistent with previous findings [8] , the single mAbs inhibited LPS-induced NFjB activation to a similar extent. Combinations of the mAbs further enhanced inhibition at all tested LPS concentrations. 9 ; 1, 10 ng); a plasmid expressing human MD-2; and pNFjB-Luc and phRG-TK control constructs; and subjected to a dualluciferase reporter assay (n = 3). The data are representative of those of three independent experiments. Bars: means AE SDs. The significance of differences was determined using Student's t-tests.
We next explored whether HT4 and HT52 bound to different sites on individual TLR4 molecules (Fig. 5B) . The cells described above were incubated with FITCconjugated HT4; almost all cell surface TLR4 was thus rendered unavailable to additional Bio-HT4 mAbs with identical epitope specificity. The cells were secondarily incubated with Bio-HT52 (with a nonoverlapping specificity). We evaluated the simultaneous binding of Bio-HT52 and FITC-HT4 to TLR4 via flow cytometry. Bio-HT52 reacted with surface TLR4 even when LRR13 was blocked by FITC-HT4, although the mean fluorescence intensity was slightly lower than that in the absence of FITC-HT4 blocking. In contrast, Bio-HT4 barely bound after blocking with FITC-HT4. These findings suggest that HT4 and HT52 bind to TLR4 simultaneously, and that this double reaction mutually enhances their individual inhibitory activities against LPS-evoked TLR4 activation.
Discussion
Toll-like receptor 4 is an attractive target to help control infectious inflammation, such as sepsis. Receptor activation may also contribute to the pathology of noninfectious chronic inflammatory diseases, such as cancer [21] , atherosclerosis [22] , and neurodegenerative conditions [23] . For many years, efforts have been devoted to the development of TLR4-targeting inhibitors as possible drugs. LPS analogs in which some acyl chains or phosphates of lipid A are deleted or modified are prime examples of such materials [10] [11] [12] 24] . The analogs bind to the binding pocket of MD-2 but do not induce the active conformational change required for TLR4 dimerization and subsequent signaling [14] . However, no competitive MD-2 antagonist has, as of yet, been successful in terms of clinical development. Other compounds that are not structural analogs of LPS have also been developed [11, 12, 25, 26] . However, most still target MD-2; specificity remains a concern. In contrast, HT4-and HT52-type mAbs directly target TLR4; they do not prevent LPS binding to MD-2 [8] .
In the present study, we found that an inhibitory epitope recognized by HT4 resides in LRR13, and differed from the epitope recognized by HT52 as expected. The region recognized by HT4 likely contributes to TLR4 activation.
Cocrystallography of LPS-bound TLR4/MD-2 showed that LRR13 does not contribute directly to LPS binding [14] . This is consistent with our previous analysis; inhibition mediated by HT4 was independent of LPS binding status [8] . LRR13 is located close to the dimerization interface created by the interaction of two TLR4s via LRRs15-17 [14] . The side chain of Asn 365 in LRR13 forms a hydrogen bond with the backbone oxygen of Ser 386 in LRR14 of other LPS-bound TLR4/MD-2 complexes [14] . The alanine substitutions of Asn 365 and other unique basic amino acids in LRR13 abrogated TLR4 activation when the mutants were overexpressed in HEK293 cells. LRR13 is thus responsible for HT4 binding and may be functionally important in terms of TLR4 dimerization.
LRR13 was recently reported to be the relevant epitope of another inhibitory anti-human TLR4 mAb, 15C1, and mAbs engineered therefrom [20, 27] . Similar to HT4, 15C1 reacts with TLR4, not MD-2, and mediates LPS binding-independent inhibition of TLR4 [20] . Some crucial amino acids of the HT4 epitope in LRR13 are shared with the 15C1 epitope (Table 1 ) [20, 27] . However, a notable difference in antigen specificity in terms of LRR12 was evident: the Tyr 328 and Asn 329 residues within LRR12 are antigenic determinants of 15C1 binding [20] but not HT4 binding. In addition, the inhibitory mechanisms of 15C1 and HT4 differ. The 15C1 mAb requires Fc-c receptor (FccR) if the inhibitory effect on LPS-stimulated cells is to be maximal [20, 28] ; we previously showed that the inhibitory action of HT4 is not greatly dependent on FccRs expression. It is currently unclear if this difference is attributable to a variation in epitope specificity. It may be that the regions to which the mAbs bind on TLR4 affect the conformational arrangement controlling the cross-linking of TLR4 and FccR. Further structural study is required.
Computational simulation of 15C1-bound TLR4/ MD-2 suggested that dimerization might be inhibited by the variable regions of 15C1 [27] . Lys 349 and Glu 369 of LRR13 were essential for inhibitory 15C1 binding via charge complementarity to Asp 103 and Lys 99 of CDR-H3 [27] . In addition, the inhibitory anti-murine TLR4 mAb 5E3 also targets the region containing LRR13 although the detailed epitope has not yet been described [29] . As Lys 349 and Glu 369 are contained in the HT4 epitope, HT4 may also block TLR4 dimerization, as assumed for 15C1 binding. However, this is not supported by the result of co-IP assays using Ba/ F3 cells expressing differentially tagged TLR4 molecules; HT4 did not inhibit LPS-induced TLR4 dimerization but rather induced the dimerization independently of LPS stimulation. Further experiments will be required to conclude that the inhibition of TLR4 dimerization is a mechanism by which HT4 and other inhibitory mAbs target LRR13. Asp 106 and Arg 101 in the CDR-H3 of HT4 may interact with Lys 349 and Glu
369
, respectively, in the LRR13 epitope. The contribution of these charge complementarities needs to be investigated to unravel the inhibitory binding of HT4. In contrast, our previous experience with epitope analysis of HT52, HTA125, and HTB2 inhibitory mAbs allows us to suggest that LRR13 is a new inhibitory epitope inherently recognized by inhibitory HT4-type mAbs and a promising target for the development of anti-TLR4 mAbs preventing activationinduced dimerization or an as-yet-unknown novel inhibitory mechanism.
CD14, a secreted and glycerophosphatidylinositolanchored LPS-binding protein enhances the LPS sensitivity of TLR4/MD-2-expressing cells [17, 30] . Recently, the catalytic mechanism underlying LPS transfer to TLR4/MD-2 by CD14 was described [30] . After delivery of monomeric LPS by the LPS-binding protein, CD14 transfers the LPS to MD-2 in a TLR4-dependent manner [30] . LRRs13-15 play essential roles in this process; details of the region(s) responsible remain unclear [30] . Such structural and mechanistic findings raise the possibility that HT4 blocks the interaction of TLR4/MD-2 and CD14/LPS by binding to LRR13. However, this is unlikely, because HT4 treatment did not reduce LPS binding to TLR4/MD-2 [8] . If the suggestion raised above is correct, LPS binding should be inhibited by HT4.
HT4 exhibits epitope specificity distinct from that of HT52 (Table 1) . We found that HT4 and HT52 bound simultaneously to LRR13 and LRR2, and that inhibition was enhanced by the mAb combination compared with that of either mAb alone, as revealed by the NFjB reporter assay. In contrast to LRR13, LRR2 (recognized by HT52) is unlikely to be directly involved in TLR4 dimerization. Therefore, the inhibitory mechanism of HT4 will differ from that of HT52 irrespective of whether HT4 inhibits receptor dimerization. Dual inhibition by anti-TLR4 mAbs differing in terms of epitope specificity and mechanism of action is attractive when intensive regulation of TLR4 activation is desired. The molecular structures of HT4-and HT52-bound TLR4/MD-2 need to be resolved to unravel the detailed mechanism underlying the enhancement of TLR4 inhibition by combinations of the HT4 and HT52 mAbs.
Alignment of TLR4 sequences reveals that Lys 349 and Lys 351 vary among many mammalian species, including human and mouse. This may confer highlevel antigenicity on human TLR4 used to immunize mice. We believe that LRR15-17 of the C-terminal domain may be optimally used to generate HT4-or 15C1-like inhibitory mAbs; co-crystallography has revealed that these LRRs constitute the principal dimerization interface [14] . However, to the best of our knowledge, the known anti-TLR4 mAbs that possibly block dimerization seem to recognize LRR13 rather than LRR15-17 [20, 27, 29] , perhaps because LRR13 is more antigenic than are LRR15-18. Alternatively, these types of inhibitory mAb may have a mechanism of inhibition independent of TLR4 dimerization.
In conclusion, we have shown that the inhibitory antihuman TLR4 mAb recognizes LRR13 to inhibit TLR4 activation. LRR13 may be a novel epitope inherent to all or many HT4-type inhibitory mAbs and a promising target for anti-TLR4 mAbs independent of LPS binding status. Dual inhibition by anti-TLR4 mAbs with different epitope specificities (i.e., HT4 for LRR13; HT52 for LRR2) mutually enhanced their inhibitory actions against LPS-induced TLR4 activation. We speculate that although HT4 inhibits TLR4 dimerization, the HT52-mediated inhibition involves an unknown novel mechanism. Alternatively, HT4 and HT52 could inhibit TLR4 activation via novel, dimerization-independent mechanisms that enhance the inhibitory activity of both of the Abs. Combination therapy using the two inhibitory mAbs may be attractive when intensive regulation of TLR4 activation is desired. We hope that our findings will aid in the design of an anti-TLR4 Ab medications with novel inhibitory mechanisms and that we have made a conceptual advance in the development of strategies to regulate TLR4 function. Kirschning 
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